Influenza vaccines have been conventionally prepared with viruses propagated in embryonated chicken eggs. Although the allantoic sac has provided a suitable medium for growth of all influenza A and B viruses in quantities sufficient for vaccine production, there are certain residual problems that suggest the desirability of additional or substitute methods. Allergy to chickens or their eggs, though uncommon, precludes the use of all presently available vaccines. Some of these egg-allergic persons need annual vaccination because they are among the "high risk group," and all allergic individuals eventually will be in this vulnerable state as they become older (6) . Furthermore, there are still technical difficulties present in harvesting allantoic fluids and maintaining sterility. Safety of embryonated chicken egg vaccines is generally accepted, but there are questions regarding the potential of contaminating avian leukosis virus even in inactivated vaccines.
Production of purified vaccines has reduced the intensity of local and systemic reactions markedly and provided more uniform concentrations of antigen (1, 8) . Described in this report are the local and systemic reactions and antibody responses to two purified influenza vaccines, one derived from bovine kidney cell culture-propagated viruses and the other from the chorioallantoic fluids of the chicken embryo. It Chicken embryo vaccine (Zonomune, Eli Lilly and Co.) was a licensed, commercially obtained lot that had been prepared with chicken embryo-propagated viruses and purified by zonal centrifugation (8 Antibody determinations. All sera were treated with an equal volume of receptor-destroying enzyme (RDE) that had been prepared as a broth culture filtrate of Vibrio cholerae. These sera were then incubated at 37 C overnight and heated at 56 C for 30 min. Viruses propagated in the chicken embryo included those contained in the vaccines and the influenza A2/Aichi 2/68 (Hong Kong) strain (6) . For hemagglutinationinhibition antibody determinations, four hemagglutinating units of virus were added to twofold dilutions of sera, and the mixture was incubated at room temperature for 30 min. Inhibition titers were determined at 4 C with human type 0 erythrocytes at a final concentration of 0.25%. The final total volume was 1 ml in tubes with hemispherical bottoms with an internal diameter of 10 mm (macrotechnique). Titers were recorded as the greatest initial dilution of antiserum that inhibited hemagglutination.
Microserology. Hemagglutination-inhibition antibody titers were also determined by a microtechnique (10) . Takatsy "tulip type" loops (0.025 ml; Cooke Engineering Co., Alexandria, Va.) and disposable plastic trays, with 96 V-shaped wells of 0.3 ml capacity each (No. IS-MVC-96, Linbro Chemical Co., New Haven, Conn.), were used. Diluent was distributed in the trays with 0.025-ml calibrated dropper pipettes (Cooke Engineering Co.), and sera were added and manually diluted with the loops in groups of eight. RESULTS
Incidence of local and systemic reactions. Comparison of reactions to bovine cell and chicken embryo vaccines is shown in Table 1 . Systemic manifestations were few and mild after either vaccine. Only three persons in each group had a temperature elevation. Other symptoms, such as headache, malaise, and chills, were minimal and infrequent and had usually disappeared by 48 hr. Pain at the site of injection was absent or mild in most subjects. Some degree of erythema was observed in about half of all subjects. Edema and induration in the inoculation area was found in 20% of the individuals.
Antigenicity of bovine kidney cell vaccine. The distributions of hemagglutination-inhibition antibody titers to the viruses contained in the bovine cell vaccine are shown in Table 2 . Relatively high prevaccination antibody titers were detected by all three antigens, and increases in titer were not of great magnitude. However, final mean antibody titers were high. Lower levels of antibody were observed with influenza A2/Aichi 2/68, and some response occurred even though this virus was not included in the vaccine.
The data were analyzed to determine the rela- tionship of the antibody levels before vaccination to those after vaccination (Table 3) . Antibody titers against all four antigens were increased to a greater degree in those with lower preimmunization levels.
Antigenicity of chicken embryo vaccine. Results similar to those described in the preceding section were obtained with chicken embryo vaccine (Table 4) . Again, relatively high levels of antibody were present prior to vaccination, but mean antibody titers were several-fold greater afterwards.
These data were also analyzed according to the antibody levels observed before vaccination (Table 5 ). Increments in mean antibody titers were greater in those persons with lower levels of prevaccination antibody. Thus, it appears that some of the individuals who received either chicken embryo or bovine cell vaccine did not have much response because they already had relatively high antibody levels.
Antibody titers determined by microtechnique.
Hemagglutination-inhibition antibody titers were determined by a microprocedure with sera obtained before and after administration of chicken embryo vaccine ( In an effort to determine the reason for these differences, simultaneous macro-and microtitrations were done with sera from a single subject immunized with influenza A2/Aichi 2/68 monovalent vaccine. Hemagglutination-inhibi-tion antibody titers were determined separately to 16, 8, 4, 2, 1, and 0.5 hemagglutinating units of virus. Sera and virus were diluted with pipettes in tubes, and samples were distributed in tubes (macro) and plastic trays (micro). For the latter, 0.025-ml amounts were dispersed with calibrated disposable pipettes. The same determinations were also made by the usual microtechnique, diluting the sera with Takatsy loops. The procedures were repeated five times and mean titers were calculated and plotted (Fig. 1) . The slopes determined by these results show that, whereas dilution with pipettes produced very similar and parallel results in tubes and trays, dilution with Takatsy loops yielded lower and unpredictable values. DISCUSSION The minimal nature of the local and systemic reactions to the bovine cell and chicken embryo vaccines described herein demonstrates the desirability of refined influenza vaccines (1, 8; J. L. Gerin et al., Fed. Proc., p. 365, 1968). Whether purification and ether treatment reduced potential toxic effects of calf kidney cell-propagated virus vaccine is not known. However, procedures of this type reduce the amount of extraneous substances and certainly provide a preferable product for injection into man. It was of interest that the chicken embryo vaccine prepared with influenza viruses purified by zonal centrifugation, but not ether-treated, caused no more reactions than did the bovine cell vaccine that had been purified by zonal centrifugation and ether-treated as well. However, the two vaccines were derived from viruses propagated in different host systems, and comparisons of the procedures utilized for purification may not be justified.
Comparable antibody responses were expected from the bovine cell and chicken embryo vaccines on the basis of their hemagglutinin contents. Whether the host cell used for propagation of the virus altered antigenicity sufficiently to affect protection induced by the vaccine has not been determined (5) . Nevertheless, it is likely that both of these vaccines would have provided protection from natural infection by virus strains related to those included in the vaccines (2, 9) .
The introduction of a new host system for vaccine production raises questions as to the presence of undesirable substances, allergens, or contaminating viruses. However, many types of biologicals, including smallpox vaccine, have been derived from bovine sources without obvious untoward effects in man.
Although chicken egg-sensitive individuals are not numerous, the "high risk" persons of this type need an influenza vaccine prepared in cells other than those of the chicken embryo. To establish efficacy of an influenza vaccine, large-scale field studies are required to determine protective effects. Whether many thousands of individuals should be given bovine kidney cell influenza vaccine until this can be determined, or whether the vaccine should be made available on a limited basis for these special persons, is uncertain. Degree of protection is predictable on the basis of antigenicity studies in man and animals.
The lower hemagglutination-inhibition antibody titers and, particularly, the smaller increments in titer obtained by the microtechnique present significant problems that must be considered in evaluating influenza vaccines by this procedure. These results most probably were caused by the diluting method. Variations in volume due to presence of microbubbles in the loops, contact of loops with the well walls, and other factors such as those described by Hirata et al. (3) might have been responsible. Thus, the savings gained from the microtechnique do not justify its use instead of the standardized and wellknown macroprocedure for measurement of hemagglutination-inhibition antibody levels, especially for evaluation of influenza vaccine.
